Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cognitive Therapy for Recurrent Depression

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Robin Jarrett, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00118404
First received: July 6, 2005
Last updated: May 13, 2014
Last verified: May 2014
Results First Received: December 12, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Depression
Interventions: Behavioral: Continuation phase cognitive therapy
Drug: Continuation phase fluoxetine
Other: Continuation phase pill placebo
Behavioral: Acute phase cognitive therapy

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
523 adults with recurrent major depressive disorder began acute phase cognitive therapy; only the 241 eligible higher-risk responders were randomized to the 3 arms above.

Reporting Groups
  Description
Continuation Phase Fluoxetine

Participants received acute phase cognitive therapy and continuation phase pill placebo

Acute phase cognitive therapy : For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.

Continuation phase pill placebo : The dosage of pill placebo was increased to 40 mg over 8 months.

Continuation Phase Cognitive Therapy

Participants received acute phase and continuation phase cognitive therapy

Acute phase cognitive therapy : For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.

Continuation phase cognitive therapy : Continuation phase cognitive therapy included 10 sessions over 8 months.

Continuation Phase Pill Placebo

Participants received acute phase cognitive therapy and continuation phase fluoxetine

Acute phase cognitive therapy : For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.

Continuation phase fluoxetine : The dosage of fluoxetine was increased to 40 mg over 8 months.

Total Total of all reporting groups

Baseline Measures
    Continuation Phase Fluoxetine     Continuation Phase Cognitive Therapy     Continuation Phase Pill Placebo     Total  
Number of Participants  
[units: participants]
  86     86     69     241  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     86     86     69     241  
>=65 years     0     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  41.6  ± 11.8     43.1  ± 11.5     43.6  ± 12.3     42.7  ± 11.8  
Gender  
[units: participants]
       
Female     57     63     42     162  
Male     29     23     27     79  
Region of Enrollment  
[units: participants]
       
United States     86     86     69     241  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Depressive Relapse or MDD   [ Time Frame: Measured at month 8 ]

2.  Primary:   Depressive Relapse/Recurrence or MDD   [ Time Frame: Measured at month 20 ]

3.  Primary:   Depressive Relapse/Recurrence or MDD   [ Time Frame: Measured at month 32 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

To our knowledge in 2014 this is of the largest, cognitive therapy responders who presented with recurrent MDD and were followed longitudinally

Proficient therapists;competency measured.

Generalizability is limited by design characteristics.



  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Robin B. Jarrett, Professor of Psychiatry
Organization: The University of Texas Southwestern Medical Center
phone: 214-648-5345
e-mail: Robin.Jarrett@UTSouthwestern.edu


Publications of Results:

Other Publications:

Responsible Party: Robin Jarrett, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT00118404     History of Changes
Other Study ID Numbers: R01 MH58397, R01MH058397, R01MH069619, R01MH058356, R01MH069618
Study First Received: July 6, 2005
Results First Received: December 12, 2013
Last Updated: May 13, 2014
Health Authority: United States: Federal Government